Development of Solid Self-Emulsifying Formulation for Improving the Oral Bioavailability of Erlotinib
- 4 August 2015
- journal article
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 17 (2) , 466-473
Abstract
To improve the solubility and oral bioavailability of erlotinib, a poorly water-soluble anticancer drug, solid self-emulsifying drug delivery system (SEDDS) was developed using solid inert carriers such as dextran 40 and Aerosil® 200 (colloidal silica). The preliminary solubility of erlotinib in various oils, surfactants, and co-surfactants was determined. Labrafil M2125CS, Labrasol, and Transcutol HP were chosen as the oil, surfactant, and co-surfactant, respectively, for preparation of the SEDDS formulations. The ternary phase diagram was evaluated to show the self-emulsifying area. The formulations were optimized using the droplet size and polydispersity index (PDI) of the resultant emulsions. Then, the optimized formulation containing 5% Labrafil M2125CS, 65% Labrasol, and 30% Transcutol was spray dried with dextran or Aerosil® and characterized for surface morphology, crystallinity, and pharmacokinetics in rats. Powder X-ray diffraction (PXRD) and differential scanning calorimetry (DSC) exhibited the amorphous form or molecular dispersion of erlotinib in the formulations. The pharmacokinetic parameters of the optimized formulations showed that the maximum concentration (C max) and area under the curve (AUC) of erlotinib were significantly increased, compared to erlotinib powder (p < 0.05). Thus, this SEDDS could be a promising method for enhancing the oral bioavailability of erlotinib.Keywords
This publication has 43 references indexed in Scilit:
- Self-nanoemulsifying drug delivery system for adefovir dipivoxil: Design, characterization, in vitro and ex vivo evaluationColloids and Surfaces A: Physicochemical and Engineering Aspects, 2011
- Clinical Pharmacokinetics of Tyrosine Kinase InhibitorsClinical Pharmacokinetics, 2011
- Preparation and Bioavailability Assessment of SMEDDS Containing ValsartanAAPS PharmSciTech, 2010
- Enhanced oral bioavailability of dexibuprofen by a novel solid Self-emulsifying drug delivery system (SEDDS)European Journal of Pharmaceutics and Biopharmaceutics, 2009
- Preparation and Evaluation of Self-Microemulsifying Drug Delivery System Containing VinpocetineDrug Development and Industrial Pharmacy, 2009
- Development of SMEDDS using natural lipophile: Application to β-Artemether deliveryInternational Journal of Pharmaceutics, 2008
- Preparation and evaluation of self-microemulsifying drug delivery system of oridoninInternational Journal of Pharmaceutics, 2008
- Design and Evaluation of Self-Emulsifying Drug Delivery Systems (SEDDS) of NimodipineAAPS PharmSciTech, 2008
- Design and Evaluation of Self-Microemulsifying Drug Delivery System (SMEDDS) of TacrolimusAAPS PharmSciTech, 2008
- Evaluation of Biologic End Points and Pharmacokinetics in Patients With Metastatic Breast Cancer After Treatment With Erlotinib, an Epidermal Growth Factor Receptor Tyrosine Kinase InhibitorJournal of Clinical Oncology, 2004